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Background: The incidence and characteristics of tuberculosis (TB) in remote areas of Papua New Guinea (PNG) are
largely unknown. The purpose of our study was to determine the incidence of TB in the Gulf Province of PNG and
describe disease characteristics, co-morbidities and drug resistance profiles that could impact on disease outcomes
and transmission.
Methods: Between March 2012 and June 2012, we prospectively collected data on 274 patients presenting to
Kikori Hospital with a presumptive diagnosis of TB, and on hospital inpatients receiving TB treatment during the
study period. Sputum was collected for microscopy, GeneXpert analysis, culture and genotyping of isolates.
Results: We estimate the incidence of TB in Kikori to be 1290 per 100,000 people (95% CI 1140 to 1460) in 2012.
The proportion of TB patients co-infected with HIV was 1.9%. Three of 32 TB cases tested were rifampicin resistant.
Typing of nine isolates demonstrated allelic diversity and most were related to Beijing strains.
Conclusions: The incidence of TB in Kikori is one of the highest in the world and it is not driven by HIV
co-infection. The high incidence and the presence of rifampicin resistant warrant urgent attention to mitigate
substantial morbidity in the region.
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GeneXpertBackground
On a global scale, a substantial proportion of the morbid-
ity and mortality caused by tuberculosis (TB) is attributed
to HIV co-infection and the emergence of drug resistance
[1]. These factors and their impact on TB incidence and
outcomes have been well studied in many African coun-
tries [2-4]. The incidence of TB in countries with geo-
graphically isolated communities such as Papua New
Guinea (PNG) is largely unknown and there is very limited* Correspondence: phuanukoonnon@wehi.edu.au; pellegrini@wehi.edu.au
1Infection and Immunity Division, Walter and Eliza Hall Institute of Medical
Research, 1G Royal Parade, Parkville, VIC 3052, Australia
8Department of Medical Biology, University of Melbourne, Parkville, VIC 3010,
Australia
Full list of author information is available at the end of the article
© 2014 Cross et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.data on drug resistance and HIV co-infection in remote
PNG communities.
The World Health Organization (WHO) reported an-
nual national incidence of TB in PNG is 346 per 100,000
population and the reported percentage of tested TB pa-
tients that are HIV positive is 11% [5]. Due to the geo-
graphical isolation of most rural areas and limited access
to health care facilities in these areas, the national figure
may not reflect true TB incidence in the many remote
regions of PNG. It is important to quantify TB incidence
in these areas as many resource development projects
are opening access to these remote communities and
modeling studies performed in the Western province of
PNG (adjacent to the Gulf province) have indicated that
areas with high disease burden can dominate the TB dy-
namics of an entire region [6]. Resource developmenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have raised concerns that TB is prevalent in the area
and this was brought to our attention. Therefore, we
sought to determine the incidence of TB, the frequency
of drug resistance and the incidence of concurrent HIV
infection in the remote Kikori community of PNG.
Methods
Setting
Kikori is a town located in the Kikori district of the Gulf
province of Papua New Guinea (Additional file 1: Figure
S1). The district is divided into 4 rural local level gov-
ernments (LLG): West Kikori LLG, East Kikori LLG,
Baimaru LLG and Ihu LLG. Kikori district encompasses
an area of 27000 km2, only 2500 km2 of which is inhab-
ited by a network of villages scattered along a river delta
system [7]. There are two hospitals in the Kikori district.
Kikori hospital primarily services West Kikori and East
Kikori LLGs and a few patients from Baimaru LLG
attend the hospital. Kikori hospital is a 90-bed hospital
administered and operated by the Christian charity
organization called Gulf Christian Services. There are 25
medical staff at Kikori hospital and volunteer expatriate
physicians sporadically visit the hospital. Over the study
period, two Australian physicians attended the hospital
to assist with clinical care and data collection. Kikori
hospital resident staff managed TB diagnosis, treatment
and care. Standard care for TB patients at Kikori gener-
ally involved hospital admission, where possible, for the
first 2-months of intensive phase treatment followed by
4 months of treatment at home. Hospitalization provides
a means of directly observing therapy and monitoring
for side effects. TB cases are segregated/isolated in a
designated TB ward that is physically separated from all
other hospital wards. TB patients are provided with hos-
pital appointments, if they reside near the hospital, or
they are referred to local health facilities for treatment
follow-up. Patients residing in very remote areas are pro-
vided with a full treatment course to be completed at
home if alternative follow-up arrangements are impracti-
cal. DOTS intervention had not been implemented at
Kikori during the study period. The Kikori district health
office TB control program was responsible for TB pa-
tient follow-up, but due to funding and manpower issues
the program was not functioning. Accessibility to Kikori
town and Kikori hospital is poor.
Study design
Between March 2012 and June 2012, we conducted an ob-
servational study to determine the incidence of TB and dis-
ease characteristics in Kikori. Patients self-presenting to
Kikori District Hospital with TB symptoms and inpatients
receiving TB treatment during the study period were in-
vited to participate in the study. Written informed consentwas obtained prior to study enrolment. The PNG \Medical
Research Advisory Committee approved the study (amend-
ment to MRAC No. 10.17) and maintains records of all
signed consent forms. All patients attending Kikori hospital
seeking medical attention were triaged as per hospital pol-
icy by medical workers. Patients with symptoms or signs
suggestive of TB, including fever, unexplained weight loss,
cough, breathlessness, lymphadenopathy, abdominal pain,
abdominal distention and neurological symptoms or signs
were then referred to an infectious diseases physician. The
specialist physician independently interviewed patients
and performed a medical examination. Patients with a
medical history and examination that was consistent
with TB were enrolled into the study as TB suspects.
A diagnosis of TB was made by an infectious diseases
physician based on the criteria listed below (Diagnosis
of TB) and TB suspects confirmed to have TB were
reclassified as TB cases. All patients prospectively di-
agnosed, as TB cases, were included in our estimation
of TB incidence.
Diagnosis of TB
Three sputum samples were collected from patients with
a productive cough. Ziehl-Neelsen (ZN) stains were per-
formed on sputum and other clinical specimens by
trained scientists. Aliquots of sputum specimens were
frozen and stored at −20°C for later analysis as described
below. Attempts were made to obtain other clinical
specimens for ZN smears; this included aspirates from
lymph nodes, swabs from discharging ears and aspirates
from other collections of pus. The WHO recommended
algorithm for the diagnosis of TB, incorporating the
international standards for TB care, were used for the
diagnosis of TB in this study [8].
Definition of TB cases and new and previously treated
cases
The patients enrolled were classified as TB suspects or
cases of TB in accordance with the WHO TB Treatment
guidelines [9]. A ‘TB suspect’ was defined as a patient
with symptoms or signs of pulmonary or extra pulmon-
ary TB and/or constitutional symptoms (loss of appetite,
weight loss, fever and fatigue). A ‘TB case’ was defined
as a patient with acid fast bacilli (AFB) detected in ZN
stained sputum (or other) specimen, or in the absence of
such laboratory confirmation, when an infectious dis-
eases physician diagnosed TB based on symptoms and
signs and decided to treat the patient with a full course
of TB therapy. Cases of TB were further classified as
new or previously treated cases [9].
Estimation of population size and TB incidence
Detailed population figures for each province in PNG
are available from the 2000 PNG National census. The
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17,779 people. This is the sum of the population in West
Kikori rural ward (n = 7579), East Kikori rural ward (n =
8788) and people residing in Baimaru Station in Baimaru
rural ward (n = 1416). The annual population growth
rate from the most recent census in 2011 is known to be
1.2% (for the Gulf province), however absolute popula-
tion figures have not yet been made available. Therefore
the population serviced by Kikori Hospital in 2012 is esti-
mated to be 20,144 people. We validated the catchment
area detailed above by confirming that all obstetrics pa-
tients attending the hospital over the study period resided
in the catchment area and that all TB cases in a retro-
spective review of hospital records (2004–2011) resided in
the defined catchment area.
HIV testing
HIV testing was performed using the Alere Determine
HIV-1/2 Ag/Ab Combo Rapid test kit HIV 1/2 STAT-PAK,
Chembio Diagnostic Systems (NY, USA), after patients
received appropriate counseling.
GeneXpert testing, microscopy culture and genotyping
Each sputum sample was analyzed by two trained mi-
croscopists for AFB at Kikori Hospital. Aliquots of all
sputum samples obtained from cases were frozen and
stored at −20°C for several months before being sent to
the PNG Institute of Medical Research (Madang) or the
Queensland Mycobacterial Reference Laboratory (MLR)
in Australia for GeneXpert assays. Sputum samples were
decontaminated according to Petroff ’s method [10] and
GeneXpert assays utilizing the Xpert MTB/RIF kit
(Cepheid, Sunnyvale California USA) were performed
as described previously [11]. Additionally, Queensland
MLR cultured all AFB smear positive sputa using BAC-
TEC™MGIT™ (Beckton Dickinson, USA) and performed
drug susceptibility testing (DST) and genotyping analyses
on all isolates that were recovered after culture. DST was
performed by the proportion method [12] using BAC-
TEC™MGIT™960 [13]. DNA was purified from cultures
using ethanol and heating to 95°C and multilocus myco-
bacterial interspersed repetitive unit variable number of
tandem repeats (MIRU-VNTR) was used for molecular
analysis and to define strains as previously described using
GenoScreen (Lille Cedex, France) MIRU-VNTR Typing
Kit – Mycobacterium tuberculosis Complex 24-loci [14].
Amplified products were detected using the AB® 3130xl
genetic analyzer with the GeneScan™ 1200 LIZ® size stand-
ard (Appliedbiosystems, Life Technologies, NY, USA).
The results were analyzed using GeneMapper® Software
(Appliedbiosystems, Life Technologies, NY, USA). The
online MIRU-VNTRplus tool (http://www.miru-vntrplus.
org) was used to calculate a neighbor-joining tree using
categorical distance measures based on 24 loci MIRU-VNTR, and to represent strains and lineage similarities as
previously described [15,16]. The loci (and corresponding
aliases) used in our studies were: 154 MIRU02, 424 Mtub04,
577 ETRC, 580 MIRU04 ETRD, 802 MIRU40, 960 MIRU10,
1644 MIRU16, 1955 Mtub21, 2059 MIRU20, 2163b
QUB11b, 2165 ETRA, 2347 Mtub29, 2401 Mtub30, 2461
ETRB, 2531 MIRU23, 2687 MIRU24, 2996 MIRU26, 3007
MIRU27 QUB5, 3171 Mtub34, 3192 MIRU31 ETRE,
3690 Mtub 39, 4052 QUB26, 4156 QUB4156 and 4348
MIRU39.
Data collection
Data were collected through patient interview for all TB
cases, and stored in a dedicated database.
Demographic variables
The following demographic variables were recorded for
each patient: age, gender, body mass index (BMI), occupa-
tion, level of education, access to mobile phone, distance
from hospital, smoking status, alcohol consumption, ex-
posure to in-house smoke and chewing of betel nut. BMI
for children and teenagers was calculated using the Cen-
ters for Disease Control and Prevention BMI online calcu-
lator tool (http://apps.nccd.cdc.gov/dnpabmi/). Exposure
to smoke from cooking fires has been associated with an
increased risk of TB [17], and spitting associated with
betel nut chewing may facilitate transmission of infection
in crowded housing [18]. Another variable captured was
ethnicity (Papuans and Highlanders), to ascertain the ethic
representation amongst TB cases. Patients receiving TB
therapy but diagnosed prior to the study commencement
were included in the description of TB characteristics and
demographics. These inpatients were specifically receiving
treatment for TB as part of their standard hospitalized
intensification phase of treatment.
Risk factors for TB
The following potential risk factors for TB were recorded
for each patient: contact with a TB case, history of pre-
vious TB treatment, crowding (number of people in co-
habitation), and absence of a BCG vaccination scar.
Distribution of TB cases
Global Positioning System (GPS) coordinates for the homes
and villages of 143 TB cases were ascertained by visiting
the villages and using a Garmin eTrex 10 GPS device. GPS
coordinates were plotted using Epi Info 7 software (Center
for Disease Control, USA).
Time trends in TB incidence in Kikori
Hospital records of the National TB Register from 2004
to 2012 were reviewed to obtain the number of patients
commenced on TB therapy every year.
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Confidence intervals for TB incidence were calculated
using both the Wilson score interval and Agresti-Coull
adjusted Wald interval methods.
Results
Patient characteristics
Two hundred and eighty seven people were approached
for informed consent. Thirteen declined consent and
274 were enrolled into the study. Of the 274 patients en-
rolled; 146 were determined to be TB cases and 128
were TB suspects (Figure 1). Forty nine of the 146 cases
were inpatients receiving TB treatment as part of their
intensification phase of therapy and the remaining 97
were prospectively diagnosed TB cases accrued over the
study period. Clinical specimens were available for ana-
lysis in 56 out of the 97 cases. In the remaining 41 cases
we were unable to collect adequate specimens for ana-
lysis. Sputum and clinical specimens from 39 of the 56
cases were AFB positive or had MTB DNA detected by
GeneXpert (Table 1). The demographic characteristics of
all TB cases are detailed in Table 2.
The median age of TB cases was 22 years and 36% of
all TB cases were under the age of 16 years. Fifty eight274
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Figure 1 Number of patients enrolled in the study, diagnostic results
sputum along with an AFB + ve lymph node aspirate. **Other clinical speci
abscess aspirate.percent of cases had had no formal education or had
only completed primary school education. Of note, 62%
of cases had access to functional mobile phones. Twenty
percent of patients had to travel for more than one day
to get to the hospital. Most patients were non-smokers
but 71% had exposure to in-house smoke from cooking
fires. Potential risk factors for TB in cases are detailed in
Table 3. Seventy three percent of cases reported having
had had contact, usually through co-habitation, with at
least one other person that was diagnosed with TB.
Many households consisted of more than 10 occupants
in a single dwelling.
Microbiology
All sputum and clinical specimens, obtained from cases,
were ZN-stained and the number of AFB was quantified
(Table 1). Eighty one percent of AFB positive sputa (25/31)
had a heavy burden of bacilli (2+ or 3+). We were able to
analyze 48 out of 53 sputum samples (5 were lost) with
GeneXpert for the prescence of Mycobaterium tuberculso-
sis (MTB) DNA and rifampicin resistance (rpoB gene mu-
tation) [10,11]. Twenty seven of the available 29 smear
positive sputa had MTB DNA detected by GeneXpert and
three of these had rifampicin resistance detected. MTB146
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ve / 
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Table 1 Specimen results for 97 prospectively accrued
cases
Clinical
specimen
Total
number
Microscopy
(numbers)
Xpert MTB/RIF
(numbers)#
New + relaspe
cases (N=80)
No clinical
specimens
33
Sputum 45 AFB smear
negative (18)
MTB DNA
detected (5/16**)
High (0)
Medium (0)
Low (2)
Very low (3)
rpOB
mutation
(0)
AFB smear
positive (27)
MTB DNA
detected (25/26*)
Scanty (2) High (11)
1+ (2) Medium (6)
2+ (11) Low (6)
3+ (12) Very low (2)
Back abscess
aspirate
1 rpOB (2)
Ear swab 1 1+
2+
Treatment
failure/defaulted
cases (N=17)
No clinical
specimens
8
Sputum 8
AFB smear
negative
(4) MTB DNA
detected
(0/3*)
AFB smear
positive
(4) MTB DNA
detected
(2/3*)
Scanty (1) High (2)
1+ (0) Medium (0)
2+ (0) Low (0)
3+ (3) Very low (0)
Lymph node
aspirate
1 1+ rpOB
mutation
(1)
#Non-sputum specimens were not analyzed by Xpert.
Lost sputum specimens could not be analyzed with Xpert (*1 lost, **2 lost).
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smear negative specimens obtained from TB cases, and
none of these were rifampicin resistant on GeneXpert
analysis (Table 1). There was a wide geographical distribu-
tion of TB cases and rifampicin resistant isolates across
the region (Additional file 1: Figure S2). One out of the
three patients with rifampicin resistance had previouslybeen treated for TB and had defaulted on therapy. The
other 2 patients had no history of TB treatment.
All sputum specimens that were AFB positive were cul-
tured and 10 specimens yielded isolates. DST confirmed
that all of the cultured isolates were sensitive to first line
drugs. Genotypic profiling was performed on these iso-
lates using MIRU-VNTR. A complete pattern was only
available for 9 isolates from cases distributed across the
Kikori region (Additional file 1: Figure S3). Most isolates
resembled Beijing strains and allelic diversity was noted at
two loci (Figure 2).
TB clinical manifestations and treatment follow-up
A complete summary of clinical symptoms and signs for
TB cases is shown in Additional file 1: Table S1. Thirty
four percent of children were severely underweight with
BMIs falling below the 1st percentile. The clinical focus
or site of TB in cases is shown in Table 4. We next
assessed factors that may be contributing to the develop-
ment of TB and impact its management. HIV screening
was performed on 105 TB cases. We identified 2 TB
cases that were co-infected with HIV (1.9%). We col-
lected data on patient management, discharge and
follow-up. By the end of the study, 37 of 146 cases (25%)
were inpatients, 17 (12%) were being managed as outpa-
tients and 7 (5%) were transferred to another hospital
closer to their home village or to mining camp clinics if
employed by the mining sector. Sixteen cases (11%)
defaulted on their therapy during the course of the study
with the most common reason being a lack of food
provision at the hospital (7/16). The remaining cases
(46%) were discharged to their home with a supply of
TB medication because of hospital bed shortages. Two
cases (1.4%) died during the study period but formal
mortality rates could not be calculated, as many cases
were lost to follow-up after hospital discharge. Only 24
of 83 cases (29%) that were discharged from hospital,
with TB therapy, attended any follow-up appointment.
Incidence of TB in Kikori
Over the course of the study period the number of TB
cases enrolled per month remained consistent, ranging
from 20 to 33 per month. To estimate TB incidence we
only included cases that were prospectively diagnosed
and commenced on treatment during the study period
(n = 97). Based on the number of new, relapse and re-
infection cases (Figure 3) over 16 weeks, we extrapolate
the TB incidence to be 1,290 cases per 100,000 people,
per year (95% CI: 1140 to 1460 per 100,000) in the
Kikori region (West and East Kikori LLGs and Baimaru
Station in the Baimaru LLG). The incidence of bacterio-
logically confirmed TB was 550 cases per 100,000 people,
per year. We next assessed if the large number of TB cases
was a recent or more chronic problem. We reviewed
Table 2 Demographic characteristics of 146 TB cases
Characteristic n (%)
Median age 22 (range: 8 months to
76 years)
Age
< 5 years old 25 (17%)
5 – 15 years old 27 (18%)
16 – 59 years old 90 (62%)
≥ 60 years old 4 (3%)
Sex
Male 66 (45%)
Female 80 (55%)
Ethnicity
Papuan 141 (97%)
Highlanders 5 (3%)
Occupation
Subsistence farmers 65 (44%)
Students 41 (28%)
Mining industry 15 (10%)
Health workers 3 (2%)
Children/unknown 40 (27%)
Level of education
University education 1 (0.7%)
Diploma 2 (1.4%)
Trade school 2 (1.4%)
High school education 23 (15.8%)
Primary school education 51 (34.9%)
No formal education 33 (22.6%)
Unknown/children under school age 34 (23.2%)
Mobile phone access
NO access to mobile phone/no
coverage
55 (37.7%)
Access to own mobile phone 51 (34.9%)
Access to family members mobile
phone
40 (27.4%)
Distance from hospital
Walk≤ 1 hour 46 (31.5%)
Boat road trip≤ 1 hour 29 (20%)
Walk > 1 hour < 1 day 0
Boat road trip > 1 hour < 1 day 44 (30%)
Walk≥ 1 day 5 (3.4%)
Boat/road trip≥ 1 day 22 (15.1%)
Smoking status*
Non smokers 104 (71.2%)
Smokers 41 (28.1%)
Unknown 1 (0.7%)
Table 2 Demographic characteristics of 146 TB cases
(Continued)
Exposure to in-house smoke**
Exposed 104 (71.2%)
No exposure 32 (21.9%)
Unknown 10 (6.9%)
Alcohol consumption
Drink alcohol 30 (20.5%)
Never drink alcohol 115 (78.8%)
Unknown 1 (0.7%)
Betel nut chewing
Does not chew betel nut 92 (63%)
Chews betel nut 53 (36.3%)
Unknown 1 (0.7%)
*Actively smoking any quantity of cigarettes prior to and leading up to illness.
**Any exposure to wood smoke from in-house fire prior to and leading up
to illness.
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cases at Kikori Hospital between 2004 – 2011 (Additional
file 1: Figure S4). The number of expected cases for 2012
based on extrapolated figures from our 16-week study is
315, and this is consistent with figures over the preceding
8 years.
Discussion
We have identified one of the highest TB incidence rates
in the world [5], much higher than the WHO figure re-
ported in 2011 [19]. We used the same case definitions
in our study that are used by the PNG government in
reporting National incidence to WHO. Our incidence
figure may be an underestimate of the true incidence, as
only patients presenting to the hospital were included in
the study and we did not perform active case finding in
the community villages. Equally, however, the inability to
bacteriologically confirm all TB cases, due to the re-
source poor setting, may have led to an over diagnosis of
TB. The incidence we report is not a temporally isolated
event coincident with our study as a review of Kikori
Hospital TB registries indicates that TB has been prob-
lematic in the area since at least 2004 (Additional file 1:
Figure S4). We used the best available tools to estimate
the population in the region but migration out of the re-
gion, variations in population growth and inaccuracies in
census data may have led to under or over estimates of
the population size used to calculate TB incidence. In con-
trast to the high TB incidence rates reported in African
countries [20], the rate in Kikori is unusual as it is not
associated with a high frequency of HIV co-infection.
Several factors are probably contributing to the high in-
cidence of TB in Kikori including: delayed presentation,
Table 3 Potential risk factors for TB in 146 TB patients
Risk factor Frequency
Contact with TB case 107 (73.3%)
No contact with TB 34 (23.3%)
Unknown 5 (3.4%)
Number of people in a household
≤ 5 35 (24.0%)
6 – 10 71 (48.6%)
> 10 40 (27.4%)
No history of TB 99 (67.8%)
Unknown 1 (0.7%)
History of previously treated TB 46 (31.5%)
Relapsed case 11/46 (23.9%)
Treatment failure 6/46 (13.1%)
Defaulted on therapy 18/46 (39.1%)
Completed treatment but uncertain if
symptoms resolved
11/46 (23.9%)
BCG scar present 99 (67.8%)
No BCG scar 41 (28.1%)
Unknown 6 (4.1%)
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burden, and the interplay between local environmental
factors and immunity. Our analysis of case demograph-
ics, disease characteristics and microbial genetics sheds
some light on the likely factors that contribute to the
Kikori TB incidence.UR
B
Delh
0.1 
Figure 2 Phylogentic tree of 9 cultured isolates from Kikori. Numb
ID numbers.Delayed presentation is evident in our study as illus-
trated by the number of complicated presentations includ-
ing disseminated TB, and the duration of symptoms. We
found literacy to be poor and in the absence of education,
cultural beliefs and folklore can delay the seeking of early
treatment for TB [21]. Additionally the remoteness of
some villages precluded early access to medical care and
compromised treatment and follow-up. Access to medical
care and follow-up could potentially be improved by con-
tacting patients that return home using mobile phone.
The remoteness of the hospital from major drug distribu-
tion centers also complicated supply of both loose and
fixed combination anti-TB drugs. The late presentation of
cases and the inefficiencies in treatment access and deliv-
ery may contribute to prolonged transmission risk and
very high infectious burdens of MTB. Factors such as
overcrowding, spitting as a cultural phenomenon, and the
heavy AFB density in most cases, could contribute to a
high infectious load which may lead to cycles of infection,
repeated exposure, onset of clinical disease, and further
transmission of disease. It is unclear what the major
drivers of clinical disease in Kikori are but factors that
may contribute to disease development include malnutri-
tion and exposure to household smoke [22,23].
Our ability to culture specimens and obtain isolates
for genotyping and other analyses was compromised by
difficulties in maintaining a cold chain during storage
and transport. Culture recovery rates in the Australian
reference laboratory were low, although the Xpert MTB/
RIF assay performed well on smear positive samples des-
pite the loss of viability. Of the ten isolates grown andHaarlem (12637/02) 
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ers in parentheses represent MIRU-VNTRplus database strain
Table 4 TB in 146 cases by site
TB site No. of
patients
Positive ZN
smear
Median age
(age range)
Disseminated TB 14 (9.6%) 1 sputum 7 (1 – 35)
1 ear swab
1 lymph
node aspirate
Pulmonary TB 72 (49.3%) 34 sputa 30 (< 1 – 76)
7 smear
negative but
MTB DNA
detected
TB Lymphadenitis 28 (19.2%) 1 aspirate 10 (< 1 – 40)
TB Abdomen/Pelvis 11 (7.5%) - 19 (2 – 45)
Cerebral TB/TB
Meningitis
6 (4.1%) - 4 (2 – 5)
TB malnutrition 6 (4.1%) - 3.5 (< 1 – 5)
TB spine 3 (2.1%) 1 aspirate 25 (8 – 47)
TB in Joint 1 (0.7%) - 6
Site unknown 5 (3.4%) - 28 (24 – 56)
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to the five first line agents, including pyrazinamide. We
were not able to recover culture isolates from the three
sputa that were found to harbour rpoB mutations. While
rifampicin resistance is considered a strong predictor of
multidrug resistant phenotype [24,25], the association is
not invariable [26] and cannot necessarily be inferred in
Kikori where no prior knowledge of drug resistance17 
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25 
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Figure 3 Flow chart for calculating incidence of TB in Kikori.patterns exist. Although sample size is small, the finding
of three rifampicin resistant isolates amongst 32 strains
tested (9%) is of concern and a systematic study of pat-
terns of drug resistance to anti-tuberculous agents is
urgently required in this patient cohort.
Whilst the exact factors driving TB in Kikori are un-
clear, it would appear that circumstances could easily
conspire to create an environment for the generation
and spread of MDRTB. This is a major concern for a
region that has limited access to, and ability to deliver
and monitor second line therapies. In the absence of
substantial improvements in infrastructure and sup-
ports, ad hoc administration of second line therapy
could result in the development of extensively drug re-
sistant TB [27]. The high TB incidence in Kikori could
rapidly promote the dominance of resistant TB strains
unless a reliable TB control program is implemented
that can detect cases, support microbiological diagnosis
including rapid detection methods such as Xpert MTB/
RIF and ensure treatment adherence and follow-up.
The more immediate consequences of the high inci-
dence of TB in Kikori and its impact on morbidity and
mortality need to be urgently addressed.
Conclusion
Our study shows that, in at least one remote region in
PNG, there is an extremely high incidence of TB, with
the potential to promote the emergence and expansion
of MDRTB. The extension of commercial resource de-
velopment projects into remote areas of PNG has helped
identify the problem but it may also serve to disseminate
it beyond these remote communities.80 
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Additional file 1: Table S1. Clinical signs and symptoms of 146 TB
patients. Figure S1. Representation of PNG with the Gulf province
highlighted in red and expanded below to show some of the rural wards
relevant to the study. Not all PNG islands and provinces are shown. Map
not to scale. Figure S2. A map of the Gulf Province showing the
distribution of 143 cases (yellow). Bottom map is an enlargement of the
indicated area showing rifampicin resistant cases (red). Figure S3.
Geographical distribution of six (of 9) genotyped isolates. Figure S4.
Number of TB cases in Kikori between 2004 and 2011.
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